High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer.
High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer.
复制标题
IV 期乳腺癌的高剂量巩固治疗与自体干细胞挽救。
DOI：
--
复制
发表时间：
1989
影响因子：
45.3
通讯作者：
J. Bitran
中科院分区：
文献类型：
--
作者：
S. Williams;R. Mick;R. Desser;J. Golick;J. Beschorner;J. Bitran
我们设计了一项II期研究，以确定由亚叶酸、长春新碱、甲氨蝶呤、多柔比星和环磷酰胺（LOMAC）组成的诱导化疗（CT），随后是环磷酰胺、塞替派和自体干细胞拯救（ASCR）的高剂量强化化疗（ICT）是否可以增加IV期乳腺癌女性的完全缓解（CR）率和生存率。29名女性入组研究; 16名患者既往接受过辅助化疗，没有患者因IV期疾病接受过化疗。发现2例患者不合格，从进一步分析中排除。在接受治疗的27例患者中，4例（15%）在LOMAC诱导后获得CR，15例（56%）获得部分缓解（PR），总缓解率为70%。在接受ICT治疗的22名患者中，12名患者达到CR，9名患者在诱导后达到PR，并在ICT后转为CR。毒性包括恶心/呕吐、粘膜炎、腹泻、皮炎、脱发和继发于中性粒细胞减少症的感染。1年生存率为60%;中位数尚未达到。研究患者的至治疗失败时间为10个月。诱导化疗后ICT和ASCR的治疗方法可提高IV期乳腺癌的CR率。CR率的增加如何导致无病生存期的延长需要进一步随访。
We designed a phase II study to determine whether induction chemotherapy (CT) consisting of leucovorin, vincristine, methotrexate, doxorubicin, and cyclophosphamide (LOMAC) followed by high-dose intensification chemotherapy (ICT) with cyclophosphamide, thiotepa, and autologous stem cell rescue (ASCR) could increase the complete response (CR) rate and survival in women with stage IV breast cancer. Twenty-nine women were enrolled on study; 16 patients had received prior adjuvant chemotherapy and no patient had received chemotherapy for stage IV disease. Two patients were found to be ineligible and excluded from further analysis. Of the 27 patients treated, four (15%) obtained a CR and 15 (56%) a partial response (PR) after LOMAC induction, for an overall response rate of 70%. Of the 22 patients treated with ICT, 12 patients had a CR, and nine were in PR after induction and converted to CR after ICT. The toxicities included nausea/vomiting, mucositis, diarrhea, dermatitis, alopecia, and infections secondary to neutropenia. The 1-year survival is 60%; the median has not yet been reached. The time to treatment failure for patients on study is 10 months. The treatment approach of ICT and ASCR following induction chemotherapy can lead to an improved CR rate in stage IV breast cancer. How this increased CR rate leads to a prolonged disease-free survival requires further follow-up.
一项针对晚期癌症患者进行二烷基化剂化疗、高剂量塞替派和环磷酰胺联合自体骨髓回输的 I-II 期研究。
DOI：
10.1200/jco.1987.5.2.260
发表时间：
1987
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
Williams,SF;Bitran,JD;Kaminer,L;Westbrook,C;Jacobs,R;Ashenhurst,J;Robin,E;Purl,S;Beschorner,J;Schroeder,C
通讯作者：
Schroeder,C